AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06631976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1ml of Depo-Medrol® injection
Description: 1ml of methylprednisolone acetate (40mg/ml) injection into subacromial bursa.
Study NCT06631976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation
Study NCT06631976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation
Study NCT06631976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerve block with 4ml of 2% lidocaine
Description: Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
Study NCT06631976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropocells® PRP injection
Description: Tropocells® PRP injection. Patients will have an 11ml venous blood sample taken. After centrifugation, the obtained preparation will be administered to the patients intratendinously.
Study NCT06631664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional physical therapy
Description: Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
Study NCT06631664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Participants received a traditional physical therapy program three times a week, for three successive months. Each session lasted for approximately 30 minutes and composed of the following: 1) Massage (spiral effleurage, longitudinal and transverse thumb effleurage for 5 minutes or until hyperemia), 2) Facilitation of muscle contraction through a variety of tactile and proprioceptive stimulation techniques - this was applied for the shoulder flexors, abductors, and external rotators, elbow flexors, and wrist/finger extensors. In patients whose lesion extend to involve C7, The facilitation techniques were also applied to elbow extensors. 3) Weight-bearing exercise, considering the developmental milestone (prone forearm support, prone full hand support). 4) Range of motion exercises - all joints of the affected side were moved through the full range of motion. 5) Sucking exercise.
Study NCT05800444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: Oral administration as tablet.
Study NCT05800444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration as tablet.
Study NCT04495452 — intervention group
Intervention type: DRUG
Intervention: Fentanyl Drug Administration
Description: Subjects will be given a standardized dose of fentanyl 2.5 mcg/kg estimated ideal body weight (males: ideal body weight = 50 kg + 2.3 kg for each inch over 5 feet. Females: Ideal body weight = 45.5 kg + 2.3 kg for each inch over 5 feet).
Study NCT05270863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRIMOCHOL™ PF
Description: A single drop in each eye at a visit.
Study NCT05270863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbachol PF
Description: A single drop in each eye at a visit.
Study NCT05270863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate
Description: A single drop in each eye at a visit.
Study NCT05238948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Substrate of CYP3A4
Study NCT05238948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-506
Description: Perpetrator of CYP3A4
Study NCT05047640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Description: Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle
Study NCT05047640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78436735 Vaccine
Description: Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle
Study NCT05344716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Intraurethral and vaginal laser treatment
Study NCT06633393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on Predicted High Myopia Risk at Age 18 Using the Myopia Prediction System
Description: At baseline and six months, participants will be provided with the results of their predicted risk of high myopia at age 18 based on the myopia prediction system.
Study NCT06633393 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback on Ophthalmic Examinations
Description: At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
Study NCT06633393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback on Ophthalmic Examinations
Description: At baseline and six months, participants will be provided with the results of their ophthalmic examinations.
Study NCT06693362 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Study NCT06693362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Study NCT06287437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.
Study NCT06287437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HRS9531 placebo
Description: HRS9531 placebo low frequency injection for 12 weeks.
Study NCT05732272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
Study NCT06693362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary.
Study NCT06693362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Anti-infective and anti-inflammatory drugs: For hospitalized patients with CAP, it is recommended to use β-lactams alone or in combination with doxycycline, minocycline, macrolides, or respiratory quinolones alone.~Corticosteroids: For patients with septic shock, hydrocortisone hemisuccinate 200 mg/day is recommended. The medication should be discontinued promptly after the correction of septic shock, and the duration of use should generally not exceed 7 days.~Antiviral drugs: Oseltamivir, acyclovir, etc.~Antipyretic drugs for those with high fever: such as aspirin, acetaminophen, indomethacin, sulindac, naproxen, etc.~Cough and expectorant drugs for cough and phlegm: ambroxol hydrochloride, acetylcysteine tablets, bromhexine, nacetylethylenediamine, pentedonate, etc.~Low molecular weight heparin: For elderly hospitalized CAP patients, the risk of deep vein thrombosis should be assessed, and low molecular weight heparin should be applied for prevention when necessary.
Study NCT06702618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule+Fulvestrant Injection
Description: TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
Study NCT06717659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic supplementation intervention
Description: probiotic supplementation will be administered, while participants continue undergoing routine pulmonary rehabilitation therapy
Study NCT06717659 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard pulmonnary rehabilitation
Description: undergo routine pulmonary rehabilitation without probiotics intervention
Study NCT06631664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)
Description: The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction.
Study NCT06630546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: first generation iStent (Glaukos, San Clemente, CA, USA) insertion
Description: In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.
Study NCT06630546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
Study NCT06630546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
Study NCT06632106 — intervention group
Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX
Study NCT06632106 — intervention group
Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor (TKIs)
Description: TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab
Study NCT06632106 — intervention group
Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
Study NCT05040750 — intervention group
Intervention type: OTHER
Intervention: laboratory investigation
Description: observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
Study NCT06480123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin drug prepared with exome originated from stem cell
Description: Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
Study NCT04899284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Intensive Bimanual Stimulation
Description: Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
Study NCT05239533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-labeled-girentuximab
Description: The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. >/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence.
Study NCT05239533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg q2wk
Study NCT05239533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab PET/CT
Description: All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration
Study NCT05239533 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 177Lu whole body (WB) planar and SPECT/CT scans
Description: 177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
Study NCT05062915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HINTS
Description: HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
Study NCT06738225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: certain serum MicroRNA biomarkers (miR-15b and miR-21)
Description: miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
Study NCT06743945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLA-R-CHP
Description: Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
Study NCT06747169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
Description: All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
Study NCT06746636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High velocity nasal insufflation
Description: • HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].
Study NCT06748950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Ketogenic Diet
Description: Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks
Study NCT06748950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-as-Usual (DAU)
Description: Participant's usual diet
Study NCT06748781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.
Description: 2.5% Calcium Hypochlorite used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
Study NCT06748781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy using Saline as root canal irrigant
Description: Saline used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
Study NCT06750003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D versus 4K laparoscopic bilateral salpingo-oophorectomy
Description: 3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
Study NCT06750003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D versus 4K laparoscopic bilateral salpingo-oophorectomy
Description: 3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
Study NCT04790929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse
Description: Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.
Study NCT04790929 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Coaching
Description: Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
Study NCT04747509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackburn exercises
Description: Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set.
Study NCT04747509 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set.
Study NCT05781854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia with bupivacaine and dexmedetomidine
Description: Epidural analgesia with bupivacaine and dexmedetomidine
Study NCT06751095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's Mobilization in End range
Description: End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint .(0-135 degree)
Study NCT05523063 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator.
Study NCT05041959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Abstinence
Description: Participants will abstain from smoking for 24 hours
Study NCT05041959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ad Lib Smoking
Description: Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
Study NCT05366699 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)
Description: lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
Study NCT06751095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization in Mid range
Description: Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint